AstraZeneca Stock Price, News & Analysis (NYSE:AZN)

$33.57 0.15 (0.45 %)
(As of 12/14/2017 04:00 PM ET)
Previous Close$33.57
Today's Range$33.30 - $33.66
52-Week Range$26.51 - $35.60
Volume4.97 million shs
Average Volume4.66 million shs
Market Capitalization$84.62 billion
P/E Ratio7.98
Dividend Yield4.10%
Beta0.72

About AstraZeneca (NYSE:AZN)

AstraZeneca logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNYSE:AZN
CUSIPN/A
Phone44-0-20-3749-5000

Debt

Debt-to-Equity Ratio1.09%
Current Ratio0.94%
Quick Ratio0.72%

Price-To-Earnings

Trailing P/E Ratio7.98
Forward P/E Ratio17.95
P/E Growth3.04

Sales & Book Value

Annual Sales$23.00 billion
Price / Sales3.70
Cash Flow$3.10 per share
Price / Cash10.82
Book Value$6.59 per share
Price / Book5.09

Profitability

Trailing EPS$2.79
Net Income$3.50 billion
Net Margins15.90%
Return on Equity34.02%
Return on Assets8.37%

Miscellaneous

Employees59,700
Outstanding Shares2,531,960,000

AstraZeneca (NYSE:AZN) Frequently Asked Questions

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a None dividend on Friday, July 28th. Investors of record on Friday, August 11th will be paid a dividend of $0.44 per share on Monday, September 11th. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend is Wednesday, August 9th. View AstraZeneca's Dividend History.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca shares split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

How were AstraZeneca's earnings last quarter?

AstraZeneca plc (NYSE:AZN) issued its quarterly earnings results on Thursday, November, 9th. The company reported $1.12 EPS for the quarter, topping the Zacks' consensus estimate of $0.57 by $0.55. The company earned $6.23 billion during the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company's revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.32 EPS. View AstraZeneca's Earnings History.

When will AstraZeneca make its next earnings announcement?

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for AstraZeneca.

Where is AstraZeneca's stock going? Where will AstraZeneca's stock price be in 2017?

18 Wall Street analysts have issued 1-year price targets for AstraZeneca's shares. Their forecasts range from $34.00 to $39.00. On average, they expect AstraZeneca's stock price to reach $36.60 in the next year. View Analyst Ratings for AstraZeneca.

Who are some of AstraZeneca's key competitors?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the folowing people:

  • Pascal Soriot, Executive Director and Chief Executive Officer (Age 57)
  • Marc Dunoyer, Executive Director, Chief Financial Officer (Age 64)
  • Fiona Cicconi, Executive Vice-President, Human Resources
  • Sean Bohen M.D., Ph.D., Chief Medical Officer, Executive Vice President - Global Medicines Development
  • Pam P. Cheng, Executive Vice President - Operations and Information Technology (Age 45)
  • Ruud Dobber, Executive Vice President, North America
  • Bahija Jallal Ph.D., Executive Vice President, MedImmune
  • Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
  • Menelas Pangalos, Executive Vice President - IMED Biotech Unit and Global Business Development
  • Leon Wang, Executive Vice President - Asia Pacific

Who owns AstraZeneca stock?

AstraZeneca's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.46%), Capital International Investors (0.39%), Epoch Investment Partners Inc. (0.29%), Wells Fargo & Company MN (0.17%), Ameriprise Financial Inc. (0.12%) and Capital Bank & Trust Co (0.11%). View Institutional Ownership Trends for AstraZeneca.

Who sold AstraZeneca stock? Who is selling AstraZeneca stock?

AstraZeneca's stock was sold by a variety of institutional investors in the last quarter, including Capital International Investors, JPMorgan Chase & Co., Todd Asset Management LLC, Epoch Investment Partners Inc., Assetmark Inc., Capital Guardian Trust Co., Sei Investments Co. and Allianz Asset Management GmbH. View Insider Buying and Selling for AstraZeneca.

Who bought AstraZeneca stock? Who is buying AstraZeneca stock?

AstraZeneca's stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Sector Gamma AS, Janus Henderson Group PLC, Point72 Asset Management L.P., Fisher Asset Management LLC, Dimensional Fund Advisors LP, Great West Life Assurance Co. Can and Wells Fargo & Company MN. View Insider Buying and Selling for AstraZeneca.

How do I buy AstraZeneca stock?

Shares of AstraZeneca can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AstraZeneca stock can currently be purchased for approximately $33.57.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $84.62 billion and generates $23.00 billion in revenue each year. The company earns $3.50 billion in net income (profit) each year or $2.79 on an earnings per share basis. AstraZeneca employs 59,700 workers across the globe.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, Cambridge X0, CB2 0AA. The company can be reached via phone at 44-0-20-3749-5000 or via email at [email protected]


MarketBeat Community Rating for AstraZeneca (AZN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  475 (Vote Outperform)
Underperform Votes:  850 (Vote Underperform)
Total Votes:  1,325
MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AstraZeneca (NYSE:AZN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 2.542.542.432.62
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
11 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $37.40$37.40$34.79$37.79
Price Target Upside: 12.47% upside11.26% upside6.54% upside9.81% upside

AstraZeneca (NYSE:AZN) Consensus Price Target History

Price Target History for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017BMO Capital MarketsSet Price TargetBuy$38.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$31.00 -> $34.00N/AView Rating Details
10/18/2017CitigroupUpgradeBuyN/AView Rating Details
10/17/2017CowenReiterated RatingHold$37.00N/AView Rating Details
10/16/2017Credit Suisse GroupUpgradeNeutral -> OutperformN/AView Rating Details
9/25/2017BNP ParibasUpgradeNeutral -> OutperformMediumView Rating Details
9/22/2017Sanford C. BernsteinReiterated RatingMkt Perform -> BuyLowView Rating Details
9/14/2017Liberum CapitalDowngradeBuy -> HoldLowView Rating Details
9/6/2017NatixisUpgradeNeutral -> BuyLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$35.00LowView Rating Details
8/9/2017InvestecUpgradeHold -> BuyLowView Rating Details
8/9/2017Piper Jaffray CompaniesReiterated RatingBuyLowView Rating Details
8/1/2017Pareto SecuritiesUpgradeSell -> HoldLowView Rating Details
7/28/2017Morgan StanleyDowngradeOverweight -> Equal WeightHighView Rating Details
7/13/2017Goldman Sachs GroupReiterated RatingSellHighView Rating Details
7/13/2017BarclaysReiterated RatingOverweightHighView Rating Details
4/10/2017Jefferies GroupReiterated RatingBuy -> HoldLowView Rating Details
2/21/2017Berenberg BankReiterated RatingBuyN/AView Rating Details
12/13/2016J P Morgan Chase & CoReiterated RatingNeutralN/AView Rating Details
11/11/2016Deutsche BankReiterated RatingBuyN/AView Rating Details
11/11/2016Beaufort SecuritiesReiterated RatingHoldN/AView Rating Details
11/10/2016Cantor FitzgeraldReiterated RatingBuyN/AView Rating Details
11/10/2016Bank of AmericaReiterated RatingBuy$41.37N/AView Rating Details
11/10/2016Shore CapitalReiterated RatingHoldN/AView Rating Details
2/28/2016Drexel HamiltonInitiated CoverageBuyN/AView Rating Details
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickN/AView Rating Details
(Data available from 12/14/2015 forward)

Earnings

AstraZeneca (NYSE:AZN) Earnings History and Estimates Chart

Earnings by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE AZN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/1/2018        
11/9/2017Q3$0.57$1.12$6.00 billion$6.23 billionViewN/AView Earnings Details
7/27/20176/30/2017$0.41$0.87$5.04 billion$5.05 billionViewN/AView Earnings Details
4/27/20173/31/2017$0.38$0.99$5.40 billion$5.41 billionViewN/AView Earnings Details
2/2/2017Q416$0.51$1.21$5.43 billion$5.59 billionViewListenView Earnings Details
11/10/2016Q316$0.48$1.32$5.95 billion$5.70 billionViewN/AView Earnings Details
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details
7/30/2015Q2$0.52$1.21$6.02 billion$5.84 billionViewListenView Earnings Details
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details
4/29/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details
10/25/2012$1.44$1.51ViewN/AView Earnings Details
7/26/2012$1.38$1.53ViewN/AView Earnings Details
4/26/2012$1.73$1.81ViewN/AView Earnings Details
2/2/2012$1.57$1.61ViewN/AView Earnings Details
10/27/2011$1.64$1.71ViewN/AView Earnings Details
7/28/2011$1.74$1.53ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

AstraZeneca (NYSE:AZN) Earnings Estimates

2017 EPS Consensus Estimate: $1.94
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.37$0.38$0.38
Q2 20171$0.42$0.42$0.42
Q3 20171$0.60$0.60$0.60
Q4 20171$0.54$0.54$0.54
(Data provided by Zacks Investment Research)

Dividends

AstraZeneca (NYSE:AZN) Dividend Information

Most Recent Dividend:9/11/2017
Annual Dividend:$1.37
Dividend Yield:4.08%
Dividend Growth:-21.20% (3 Year Average)
Payout Ratio:49.10% (Trailing 12 Months of Earnings)
73.26% (Based on This Year's Estimates)
76.11% (Based on Next Year's Estimates)
Dividend Payments by Quarter for AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2017None$0.442.98%8/9/20178/11/20179/11/2017
2/3/2017semiannual$0.956.81%2/15/20172/17/20173/20/2017
7/29/2016$0.448/10/20168/12/20169/12/2016
2/5/2016$0.932/17/20162/19/20163/21/2016
2/10/2015semiannual$1.905.57%2/18/20152/20/20153/23/2015
8/1/2014semiannual$0.902.48%8/13/20148/15/20149/15/2014
2/10/2014special$1.902.79%2/19/20142/21/20143/24/2014
8/2/2013semiannual$0.903.52%8/14/20138/16/20139/16/2013
2/1/2013special$1.903.72%2/13/20132/15/20133/18/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AstraZeneca (NYSE AZN)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

AstraZeneca (NYSE AZN) News Headlines

Source:
DateHeadline
AstraZeneca’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia TrialsAstraZeneca’s CALQUENCE® (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukemia Trials
finance.yahoo.com - December 12 at 11:40 AM
ETFs with exposure to AstraZeneca Plc : December 11, 2017ETFs with exposure to AstraZeneca Plc : December 11, 2017
finance.yahoo.com - December 11 at 3:33 PM
AstraZeneca plc (AZN) Expected to Announce Quarterly Sales of $5.76 BillionAstraZeneca plc (AZN) Expected to Announce Quarterly Sales of $5.76 Billion
www.americanbankingnews.com - December 10 at 8:58 AM
AstraZeneca's COPD Drug Succeeds in Label Expansion StudyAstraZeneca's COPD Drug Succeeds in Label Expansion Study
finance.yahoo.com - December 5 at 11:48 AM
AstraZeneca’s (AZN) Solid Earnings Visibility Keep it a BuyAstraZeneca’s (AZN) Solid Earnings Visibility Keep it a Buy
investorplace.com - December 1 at 4:30 PM
Astrazeneca PLC (AZN) Receives Consensus Rating of "Hold" from AnalystsAstrazeneca PLC (AZN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 30 at 7:48 PM
Celebrity Trainer and Author Bob Harper Teams up with AstraZeneca to Connect with Fellow Heart Attack SurvivorsCelebrity Trainer and Author Bob Harper Teams up with AstraZeneca to Connect with Fellow Heart Attack Survivors
finance.yahoo.com - November 30 at 11:41 AM
AstraZenecas Tagrisso Label Expansion Filing Accepted by EMAAstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
finance.yahoo.com - November 29 at 11:29 AM
AstraZeneca's Tagrisso Label Expansion Filing Accepted by EMAAstraZeneca's Tagrisso Label Expansion Filing Accepted by EMA
finance.yahoo.com - November 29 at 11:29 AM
ETFs with exposure to AstraZeneca Plc : November 29, 2017ETFs with exposure to AstraZeneca Plc : November 29, 2017
finance.yahoo.com - November 29 at 11:29 AM
AstraZeneca submits Tagrisso application in JapanAstraZeneca submits Tagrisso application in Japan
www.marketwatch.com - November 27 at 3:57 PM
AstraZeneca Submits SNDA In Japan For Tagrisso In 1st-line NSCLC - Quick FactsAstraZeneca Submits SNDA In Japan For Tagrisso In 1st-line NSCLC - Quick Facts
www.nasdaq.com - November 27 at 3:57 PM
AstraZeneca forms joint venture in ChinaAstraZeneca forms joint venture in China
finance.yahoo.com - November 27 at 3:57 PM
AstraZeneca steps up China push with new drug joint ventureAstraZeneca steps up China push with new drug joint venture
finance.yahoo.com - November 27 at 3:57 PM
Astrazeneca (AZN) & Its Peers Head-To-Head ContrastAstrazeneca (AZN) & Its Peers Head-To-Head Contrast
www.americanbankingnews.com - November 27 at 11:26 AM
Nektar (NKTR) Stock Up More than 300% This Year: Here's WhyNektar (NKTR) Stock Up More than 300% This Year: Here's Why
finance.yahoo.com - November 24 at 3:36 PM
Performance of AstraZeneca’s Oncology Segment in 3Q17Performance of AstraZeneca’s Oncology Segment in 3Q17
finance.yahoo.com - November 20 at 5:34 PM
AstraZeneca’s Other Products in 3Q17AstraZeneca’s Other Products in 3Q17
finance.yahoo.com - November 20 at 5:34 PM
Foreign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon MissForeign Stock Roundup: JD.com Beats Estimates, Petrobras & Infineon Miss
finance.yahoo.com - November 20 at 5:34 PM
Roche win boosts case for adding chemo to cancer immunotherapyRoche win boosts case for adding chemo to cancer immunotherapy
finance.yahoo.com - November 20 at 5:34 PM
For Parkinsons Patients Like Jesse Jackson, Artificial Intelligence Shows Real PromiseFor Parkinson's Patients Like Jesse Jackson, Artificial Intelligence Shows Real Promise
finance.yahoo.com - November 20 at 5:34 PM
Zacks: Brokerages Anticipate Astrazeneca PLC (AZN) to Post $0.46 Earnings Per ShareZacks: Brokerages Anticipate Astrazeneca PLC (AZN) to Post $0.46 Earnings Per Share
www.americanbankingnews.com - November 20 at 1:38 PM
Critical Contrast: Astrazeneca PLC (AZN) versus Its PeersCritical Contrast: Astrazeneca PLC (AZN) versus Its Peers
www.americanbankingnews.com - November 19 at 7:14 PM
Astrazeneca PLC (AZN) PT Set at $38.00 by BMO Capital MarketsAstrazeneca PLC (AZN) PT Set at $38.00 by BMO Capital Markets
www.americanbankingnews.com - November 19 at 11:14 AM
AstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales TacticsAstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales Tactics
www.rttnews.com - November 18 at 4:12 PM
Astrazeneca PLC Target of Unusually High Options Trading (AZN)Astrazeneca PLC Target of Unusually High Options Trading (AZN)
www.americanbankingnews.com - November 18 at 4:28 AM
Why It’s Time to Put Pfizer Inc. Stock on Your WatchlistWhy It’s Time to Put Pfizer Inc. Stock on Your Watchlist
finance.yahoo.com - November 17 at 4:01 PM
ETFs with exposure to AstraZeneca Plc : November 17, 2017ETFs with exposure to AstraZeneca Plc : November 17, 2017
finance.yahoo.com - November 17 at 4:01 PM
AstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales Tactics - NasdaqAstraZeneca Reportedly In Talks To Settle Texas Lawsuit Over Sales Tactics - Nasdaq
www.nasdaq.com - November 17 at 9:30 AM
Texas Lawsuit Claims This Drugmaker Pushed Antipsychotic to KidsTexas Lawsuit Claims This Drugmaker Pushed Antipsychotic to Kids
finance.yahoo.com - November 17 at 9:30 AM
How AstraZeneca’s Growth Platforms Performed in 3Q17How AstraZeneca’s Growth Platforms Performed in 3Q17
finance.yahoo.com - November 17 at 9:30 AM
AstraZeneca’s Cardiovascular and Metabolic Diseases SegmentAstraZeneca’s Cardiovascular and Metabolic Diseases Segment
finance.yahoo.com - November 17 at 9:29 AM
AstraZenecas fasenra gets FDA approvalAstraZeneca's fasenra gets FDA approval
www.marketwatch.com - November 16 at 9:42 PM
AstraZenecas Faslodex Gets FDA Nod for Use With VerzenioAstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
finance.yahoo.com - November 16 at 4:38 PM
Why AstraZeneca’s Revenues Rose in 3Q17Why AstraZeneca’s Revenues Rose in 3Q17
finance.yahoo.com - November 16 at 4:38 PM
AstraZeneca’s Performance by Segment in 3Q17AstraZeneca’s Performance by Segment in 3Q17
finance.yahoo.com - November 16 at 4:38 PM
AstraZenecas Faslodex Gets FDA Nod for Use With Verzenio - NasdaqAstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio - Nasdaq
www.nasdaq.com - November 16 at 11:46 AM
FASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with AbemaciclibFASLODEX® (fulvestrant) Receives US FDA Approval for the Treatment of Advanced Breast Cancer in Combination with Abemaciclib
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDAAstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA
finance.yahoo.com - November 16 at 11:46 AM
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with LoxoPharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca Plc :AZN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017AstraZeneca Plc :AZN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 16, 2017
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca's Faslodex Gets FDA Nod for Use With VerzenioAstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca ticks another box as U.S. approves severe asthma drugAstraZeneca ticks another box as U.S. approves severe asthma drug
finance.yahoo.com - November 16 at 11:46 AM
AstraZeneca’s Valuation after 3Q17 EarningsAstraZeneca’s Valuation after 3Q17 Earnings
finance.yahoo.com - November 16 at 11:46 AM
FASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic AsthmaFASENRA (benralizumab) Receives US FDA Approval For Severe Eosinophilic Asthma
finance.yahoo.com - November 15 at 1:38 AM
AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate - NasdaqAstraZeneca Gets Positive CHMP Opinion for Asthma Candidate - Nasdaq
www.nasdaq.com - November 14 at 1:45 AM
[$$] AstraZeneca lifts earnings guidance as sales decline slows[$$] AstraZeneca lifts earnings guidance as sales decline slows
finance.yahoo.com - November 11 at 4:09 PM
AstraZeneca rides China wave as rival GlaxoSmithKline strugglesAstraZeneca rides China wave as rival GlaxoSmithKline struggles
finance.yahoo.com - November 11 at 4:09 PM
AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS ViewAstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View
finance.yahoo.com - November 11 at 4:09 PM
Astras Externalized Revenue Is UnsustainableAstra's Externalized Revenue Is Unsustainable
finance.yahoo.com - November 11 at 4:09 PM

SEC Filings

AstraZeneca (NYSE:AZN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AstraZeneca (NYSE:AZN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AstraZeneca (NYSE AZN) Stock Chart for Thursday, December, 14, 2017

Loading chart…

This page was last updated on 12/14/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.